---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-005554"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2026-02-06T23:59:59+00:00"
generated_at: "2026-05-16T04:06:42.101781+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics appoints Gregg C. E. Johnson as independent director

## Summary
- Gregg C. E. Johnson appointed independent director effective Feb 4, 2026; will serve on Compensation Committee.
- Annual cash fee of $48,000 plus $5,000 per committee membership; eligible for stock options under 2024 Equity Incentive Plan.
- Johnson previously served as Secretary (2016-2020) and director (2016-2018) of Vivos; has law degree and experience in emerging companies.

## SEC filing metadata
- accession: 0001493152-26-005554
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2026-02-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315226005554/0001493152-26-005554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315226005554/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-005554
- JSON: https://secwatch.observer/filing/0001493152-26-005554.json
- Plain text: https://secwatch.observer/filing/0001493152-26-005554.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.